## VRTX: Vertex Pharmaceuticals Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($439.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12**
- Source: Business Wire | 20251222T210217 | Neutral | Relevance: 100%
- Vertex Pharmaceuticals Incorporated announced that its CEO and President, Dr. Reshma Kewalramani, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. ET. A live webcast of the presentation will be available on the Vertex website, with a replay archived afterward. The company is a global biotechnology firm focusing on transformative medicines for serious diseases.

**2. Flputnam Investment Management Co. Sells 3,065 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251221T114028 | Somewhat-Bullish | Relevance: 100%
- Flputnam Investment Management Co. has reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 8.1%, selling 3,065 shares. Despite this, institutional ownership remains high at 90.96%, with other major funds increasing their positions. The company reported an EPS beat and revenue growth, and analysts maintain a "Moderate Buy" rating with an average target price of $498.42.

**3. Congress Asset Management Co. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251221T093654 | Neutral | Relevance: 100%
- Congress Asset Management Co. reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 14.4% in the third quarter, selling 27,129 shares and leaving it with 160,875 shares valued at approximately $63.0 million. Despite this, analysts largely maintain a "Moderate Buy" rating with an average price target of $498.42, and several firms have recently raised their price targets or upgraded the stock. However, significant insider selling has occurred, with insiders offloading 151,073 shares worth about $67.33 million in the last quarter.

**4. Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12**
- Source: Yahoo Finance | 20251222T210854 | Somewhat-Bullish | Relevance: 99%
- Vertex Pharmaceuticals Incorporated announced that its CEO and President, Dr. Reshma Kewalramani, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET. A live webcast of the presentation will be available on Vertex's website for investors, with a replay archived afterward. The company, known for its transformative medicines for serious diseases, will share updates on its approved therapies and robust clinical pipeline.

**5. Foster Victor Wealth Advisors LLC Has $13.66 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251221T120128 | Somewhat-Bullish | Relevance: 96%
- Foster Victor Wealth Advisors LLC significantly increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 33.5% in Q3, now holding 33,857 shares valued at $13.66 million. Despite insider selling totaling $67.33 million in the last 90 days, the company reported a strong quarterly beat with EPS of $4.80 and revenue of $3.08 billion, prompting a "Moderate Buy" consensus rating and an average price target of $498.42 from analysts.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $515 | $460 | +12% |
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 10 ($11.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Heavy insider selling: $11M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 22.7x stretched relative to 10% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($11.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $117.7B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 22.7 |
| Current P/E | 24.9 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.9% to 0.1% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.15% (CS: 72) | Neutral |
| RSI_14 | 61.6 | Neutral |
| MACD Histogram | 0.43 | Bullish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.062x | Above |
| vs SMA200 | 1.042x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $459.21
- **Stop Loss:** $439.27 (4.3% risk)
- **Target:** $479.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $27,552.60
- **Portfolio %:** 27.55%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*